Keywords
How to Cite
Abstract
During the period 2006 to 2017 years 86 patients with neuroendocrine pancreatic tumors were observed and treated. 25 (29,1%) patients underwent only chemotherapy due to generalized tumor process or severe concomitant somatic status. 61 (70,9%) patients with neuroendocrine pancreatic tumors underwent surgical treatment. In 34 patients tumors were localized in the body and tail, in 27 - in the head of the pancreas. Women predominated among patients (n = 41), the average age of the patients was 51 ± 3.1 years. Synchronous metastatic liver metastases were detected in 33 (54,1%) of 61 patients, with the size of the primary tumor from 10 to 73 mm. In 47 (77%) neuroendocrine pancreatic tumors were regarded as non-functioning. Radical surgery was performed in 24 patients of 61 (39,3%) with tumor sizes from 11 to 128 mm (average 56 ± 21 mm), cytoreductive surgery was performed in 37 (60.7%) patients. Patients with locally advanced neuroendocrine pancreatic tumors (n = 13) and neuroendocrine pancreatic tumors with synchronous liver metastases (n = 33) undergone combined treatment (n = 46). Combined treatment was performed by means of intra-arterial selective oil chemoembolization and chemoinfusion, supplemented with one or several local methods effects: cytoreductive surgery and radiofrequency ablation (n = 8). 6 (12.2%) of patients with high, moderately and low-grade tumors died after the operation in period from 7 to 63 months from progression of disease. 43 (87.8%) patients survived in period from 4 to 112 months, 32 patients still alive without signs of disease progression. Because of recurrence in five patients (11.9%) repeated operations were performed. One patient (2.4%) underwent conformal radiation therapy. Life expectancy after surgery in patients with low-grade neuroendocrine cancer of the pancreas ranged from 3 to 16 months, and the median survival was 8.3 ± 1.2 months.
References
Делекторская В.В. Молекулярно-биологические маркеры в диагностике нейроэндокринных опухолей//Молек. мед. -2015. -№ 2. -С. 44-53.
Комарова Л.Е., АРИОН А.И., Таболиновская Т.Д. и др. Госпитальный регистр нейроэндокринных опухолей в ФГБУ «РОНЦ им. Н.Н. Блохина» Минздрава России//рос. онк. ж. -2016. -Т. 6. -№ 21. -С. 312-318.
Майстренко Н.А., Ромащенко П.Н., Лысанюк М.В. Современные технологии в диагностике и лечении нейроэндокринных опухолей поджелудочной железы//Вест. хир. -2015. -Т. 174. -№1. -С. 26-33.
Нейроэндокринные опухоли. общие принципы диагностики и лечения/Под ред. В.А. Горбуновой. -М.: Кодекс, 2015. -456 с.
Павловский А.В., Гранов Д.А., Урбанский А.И. и др. Чрескожная тонкоигольная биопсия в диагностике рака поджелудочной железы//Вопр. онкологии. -2003. -Т. 49. -№ 4. -С. 487-492.
Поликарпов А.А., Таразов П.Г., Гранов Д.А., ЗеадехАбдель-Халег. Артериальная эмболизация при метастазах гормонпродуцирующих опухолей печени//рос. онкол. журн. -2000. -№ 1. -С. 16-19.
Попов С.А., Павловский А.В., Урбанский А.И. Эффективность чрескожной трепанобиопсии в диагностике новообразований поджелудочной железы//Вестник хирургии. -2014. -Т 173. -№ 1. -С. 84-88.
Симоненко В.Б. Карциноиды и нейроэндокринные опухоли//В.Б. Симоненко, П.А. Дулин, М.А. Маканин. -Москва, ОАО «издательство Медицина», 2008. -176 с.
Таразов П.Г., Поликарпов А.А., Гранов Д.А. Артериальная химиоэмболизация в лечении больных метастазами злокачественного карциноида в печени//Анн. хирургич. гепатол. -2010. -Т. 15. -№ 3. -С. 19-24.
Bertani E., Fazio N., Botteri E. et al. Resection of the primary pancreatic neuroendocrine tumor in patients with unresectable liver metastases: possible indications for a multimodal approach//surg. -2014. -Vol. 155(4). -P. 607-614.
Brunner S.M., Weber E., Werner J.M. et al. neuroendocrine tumors of the pancreas: a retrospective single-center analysis using the ENETs TNM-classification and immunohistochemical markers for risk stratification//BMC surg. -2015. -Vol. 15. -P 49.
Curran T., Pockaj B.A. et al. Importance of lymph node involvement in pancreatic neuroendocrine tumors: impact on survival and implications for surgical resection//J. Gastrointest. Surg. -2015. -Vol. 19(1). -P. 152-160.
Deppen A., Liu E., Blume J.D. et al. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors//J. Nucl. Med. -2016. -Vol. 57(5). -P. 708-714.
Do Minh D., Chapiro J., Gorodetski B. et al. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model//Eur. Radi ol. -2017. -Vol. 27(12). -P 4995-5005.
Kennedy A., Bester L., Salem R. et al. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumors (NET): guidelines from the NET-Liver-Metastases Consensus Conference//HPB. -2015. -Vol. 17. -P. 29-37.
Kuo J.H., Lee J.A. et al. Nonfunctional pancreatic neuroendocrine tumors//Surg. Clin. N. Am. -2014. -Vol. 94(3). -P 689-708.
Meng Z., Ping Z., Xiaodan s. et al. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study//BMC Endocr. Disord. -2017. -Vol. 17. -P 39.
Yao J.C., Hassan M., Phan A. et al. one hundred years after «carcinoid»: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United states//J. Clin. oncol. -2008. -Vol. 26(18). -P. 30633072.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2018